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Temporal changes in inflammatory mitochondriaenriched microRNAs following traumatic brain injury
and effects of miR-146a nanoparticle delivery
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Abstract

Accepted: March 16, 2020

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate post-transcriptional
gene expression and contribute to all aspects of cellular function. We previously reported
that the activities of several mitochondria-enriched miRNAs regulating inflammation (i.e.,
miR-142-3p, miR-142-5p, and miR-146a) are altered in the hippocampus at 3–12 hours
following a severe traumatic brain injury. In the present study, we investigated the temporal
expression profile of these inflammatory miRNAs in mitochondria and cytosol fractions at
more chronic post-injury times following severe controlled cortical impact injury in rats. In
addition, several inflammatory genes were analyzed in the cytosol fractions. The analysis
showed that while elevated levels were observed in cytoplasm, the mitochondria-enriched
miRNAs, miR-142-3p and miR-142-5p continued to be significantly reduced in mitochondria
from injured hippocampi for at least 3 days and returned to near normal levels at 7 days
post-injury. Although not statistically significant, miR-146a also remained at reduced levels
for up to 3 days following controlled cortical impact injury, and recovered by 7 days. In
contrast, miRNAs that are not enriched in mitochondria, including miR-124a, miR-150,
miR-19b, miR-155, and miR-223 were either increased or demonstrated no change in their
levels in mitochondrial fractions for 7 days. The one exception was that miR-223 levels were
reduced in mitochondria at 1 day following injury. No major alterations were observed
in sham operated animals. This temporal pattern was unique to mitochondria-enriched
miRNAs and correlated with injury-induced changes in mitochondrial bioenergetics as
well as expression levels of several inflammatory markers. These observations suggested a
potential compartmental re-distribution of the mitochondria-enriched inflammatory miRNAs
and may reflect an intracellular mechanism by which specific miRNAs regulate injuryinduced inflammatory signaling. To test this, we utilized a novel peptide-based nanoparticle
strategy for in vitro and in vivo delivery of a miR-146a mimic as a potential therapeutic
strategy for targeting nuclear factor-kappaB inflammatory modulators in the injured brain.
Nanoparticle delivery of miR-146a to BV-2 or SH-SY5Y cells significantly reduced expression
of TNF receptor-associated factor 6 (TRAF6) and interleukin-1 receptor-associated kinase 1
(IRAK1), two important modulators of the nuclear factor-kappaB (NF-κB) pro-inflammatory
pathway. Moreover, injections of miR-146a containing nanoparticles into the brain
immediately following controlled cortical impact injury significantly reduced hippocampal
TNF receptor-associated factor 6 and interleukin-1 receptor-associated kinase 1 levels. Taken
together, our studies demonstrate the subcellular alteration of inflammatory miRNAs after
traumatic brain injury and establish proof of principle that nanoparticle delivery of miR-146a
has therapeutic potential for modulating pro-inflammatory effectors in the injured brain. All
of the studies performed were approved by the University of Kentucky Institutional Animal
Care and Usage Committee (IACUC protocol # 2014-1300) on August 17, 2017.
Key Words: cell permeable peptide-delivery; controlled cortical impact; inflammatory
pathway; mitochondria-associated microRNA; nanoparticle; nuclear factor-kappaB;
traumatic brain injury
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Introduction
Traumatic brain injury (TBI) elicits a rapid and pronounced
neuroinflammatory response propagated, in part, by resident

microglia as well as circulating monocytes that differentiate
into macrophages along a continuum ranging from
cytotoxic pro-inflammatory to reparative anti-inflammatory
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phenotypes. These cells have been consistently linked with
pro-inflammatory signaling processes underlying chronic
degenerative changes after TBI (Ziebell and MorgantiKossmann, 2010; Kumar and Loane, 2012; Woodcock and
Morganti-Kossmann, 2013). The expression of reparative
myeloid cells peaks at approximately one week following injury
and then declines, while the pro-inflammatory phenotype may
persist for months to years (Ziebell and Morganti-Kossmann,
2010; Kumar and Loane, 2012; Johnson et al., 2013;
Woodcock and Morganti-Kossmann, 2013; Kumar et al., 2015).
This differential expression pattern favoring prolonged proinflammation limits tissue repair and is associated with poor
functional outcomes. Therefore, strategies that effectively
limit detrimental pro-inflammatory responses, while
maintaining the reparative potential of macrophages, have
clear therapeutic potential (Ziebell and Morganti-Kossmann,
2010; Kumar and Loane, 2012; Woodcock and MorgantiKossmann, 2013). In support of this, experimental approaches
that mitigate pro-inflammatory signaling after severe TBI can
significantly reduce tissue pathology and promote functional
recovery (Lloyd et al., 2008; Hsieh et al., 2014; Bachstetter et
al., 2015; Morganti et al., 2015). However, identifying tools
that shift these myeloid effectors towards a reparative bias
with a high degree of specificity and efficacy has been very
limited. One novel strategy with high translational potential
is the use of nanoparticle technologies to deliver microRNAs
(miRNAs) targeting genes that regulate inflammatory signaling
(O’Neill et al., 2011; Contreras and Rao, 2012; O’Connell et al.,
2012).
MiRNAs are evolutionally conserved non-coding short RNA
molecules that bind recognition elements in messenger RNA
(mRNA) and fine tune post-transcriptional gene expression
(Bartel, 2004; Huntzinger and Izaurralde, 2011). MiRNAs
regulate all aspects of cellular function, and disruption of
miRNA activity contributes to many disease states including
neurodegeneration (Calin and Croce, 2006; Nelson et
al., 2008; Liu and Xu, 2011; Hata, 2013). MiRNA-based
therapeutic approaches have been tested and several
are currently in clinical trials targeting hepatitis C, type 2
diabetes, and several cancer types (Rupaimoole and Slack,
2017). Therefore, the ability of miRNAs to regulate expression
of genes contributing to TBI-related neuroinflammatory
signaling makes them attractive therapeutic candidates. Using
mouse and rat models, we and others have reported that a
number of miRNAs are altered in cortex and hippocampus
following TBI (Redell et al., 2009; Hu et al., 2012; Liu et al.,
2014; Sabirzhanov et al., 2014; Wang et al., 2015, 2017;
Harrison et al., 2017; Kumar et al., 2017). The studies from
our lab are the first to demonstrate that a subset of miRNAs
regulating cellular inflammatory activities (e.g., miR-146a) is
enriched in brain mitochondria fractions (Wang et al., 2015,
2017). We also reported that levels of these miRNAs display a
compartmental shift from the mitochondria to the cytosol as
early as 3–12 hours following TBI (Wang et al., 2015, 2017),
which corresponds to the temporal loss in mitochondrial
function after acute TBI (Sullivan et al., 1998, 2007; Singh et
al., 2006). These observations suggest an interaction between
mitochondrial function and miRNA-mediated inflammatory
signaling at early time points following TBI.
MiR-146a plays a significant role in regulating levels of
inflammatory cytokines and related signaling events in a
manner that favors expression of the reparative macrophage
phenotype (Cui and Liu, 2015). However, the relationship
between miRNA changes and inflammatory signaling in
the hippocampus beyond 12 hours following TBI is not
known. Moreover, strategies that modify miRNA signaling to
effectively promote expression of the reparative macrophage

phenotype are lacking. Therefore, the aim of this study was
to quantify changes of select miRNAs and inflammatory
genes isolated from the hippocampus at different time points
following severe TBI. In addition, we tested the ability of miR146a nanoparticle delivery to target the nuclear factor-kappaB
(NF-κB) modulators TNF receptor-associated factor 6 (TRAF6)
and interleukin-1 receptor-associated kinase 1 (IRAK1) in vitro
as well as in vivo after severe TBI.

Materials and Methods
Animals and TBI procedures
All of the studies performed were approved by the University
of Kentucky Institutional Animal Care and Usage Committee
(IACUC protocol # 2014-1300) on August 17, 2017.
Additionally, the Division of Laboratory Animal Resources
at the University is accredited by the Association for the
Assessment and Accreditation for Laboratory Animal Care,
International (AAALAC, International) and all experiments
were performed with its guidelines. All animal experiments
are in compliance with ARRIVE guidelines and experiments
are carried out in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, revised 1996). Thirty young
adult male (7–10 weeks old) Sprague-Dawley rats weighing
~250 g (Charles River Laboratories, Wilmington, MA, USA)
were acclimated for 7 days prior to experimentation. Rats
were allowed free access to food/water and housed in a
temperature-controlled room on a 12-hour light/dark cycle.
The surgical and brain injury procedures performed in this
study followed our previously published protocols (Sullivan
et al., 1999; Wang et al., 2015). The controlled cortical
impact (CCI) injury is a well-established brain injury model
utilized by numerous researchers and, as such, allows for
comparison of outcomes across studies (Dixon et al., 1991).
Briefly, experimental rats were anesthetized with a dose
of 4% isoflurane (Covetrus, Portland, ME, USA) via a nose
cone and were positioned in a stereotaxic frame (David
Kopf, Tujunga, CA, USA). The surgical and CCI procedure was
conducted under sterile conditions and continued supplied
dose of 2.5% isoflurane throughout the procedure. The core
body temperature of the experimental rats was kept at 37°C
during the procedures and the post-surgical/CCI recovery
period. An incision was made along the midline in a rostracaudal orientation to expose the skull. A 6-mm craniotomy
was then created lateral to center between bregma and
lambda. The brain injury was performed by driving a 5 mm
diameter rod tip at 3.5 m/s velocity to compress the cortex
to a depth of 2.0 mm using a pneumatically controlled
impacting device (Precision Systems and Instrumentation,
Fairfax Station, VA, USA). This procedure resulted in a severe
injury consistent with previous studies (Baldwin et al., 1997;
Davis et al., 2008; Gilmer et al., 2009) and characterized by
physical damage to the cortex and the presence of neuronal
damage to the underlying hippocampus. Following injury,
surgical absorbable hemostat was placed in the craniotomy
and a plastic disc adhered to the skull to cover and stabilize
the craniotomy site. Sham animals received identical exposure
to the surgical procedures, but without brain injury. The
surgeries were conducted at the same time of day, 2 days
apart with three CCI and two sham operations performed at
each time. Animals (total n = 6 per group for CCI, n = 4 per
group for sham surgery) were euthanatized with CO2 at 1, 3,
or 7 days following injury and the ipsilateral and contralateral
hippocampi were rapidly removed for isolation of the
mitochondria and cytosolic fractions.
Cytosolic and mitochondrial fractionation
For mitochondrial bioenergetics and the miRNA and mRNA
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expression studies, the mitochondria and cytosol fractions
were obtained from the hippocampus following a previously
described Ficoll density gradient procedure (Pandya et
al., 2009). Briefly, harvested hippocampal tissue was
homogenized in pre-cooled mitochondrial isolation buffer (215
mM mannitol, 75 mM sucrose, 0.1% bovine serum albumin
(BSA), 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), 1 mM ethylene glycol-bis(β-aminoethyl ether)N,N,N′,N′-tetraacetic acid (EGTA); pH adjusted to 7.2 with
KOH). The homogenate was then centrifuged at 1300 × g for
3 minutes to remove tissue debris and nuclei. The resulting
supernatant was then subjected to a centrifugation at 13,000
× g for 10 minutes to obtain crude mitochondrial pellets and
the supernatant was saved as cytosol (CT) fraction. The resuspended crude mitochondria sample was then placed into
a nitrogen cell disruption chamber for 10 minutes (1200 psi)
to rupture and release synaptosomal mitochondria (Brown
et al., 2004). The crude mitochondria fraction was then
laid over a discontinuous Ficoll gradient (7.5% + 10%) and
further separated by centrifugation using a SW 55Ti rotors
at 100,000 × g for 30 minutes. The mitochondria pellet (MT)
was rinsed in mitochondrial isolation buffer in the absence of
EGTA and centrifuged at 10,000 × g at 4°C for 10 minutes and
resuspended in the same buffer to achieve a concentration of
~10 mg/mL. The protein content of the various fractions was
analyzed using BCA protein assay kit (ThermoFisher, Waltham,
MA USA).
Mitochondria bioenergetics
Mitochondrial bioenergetics were assessed using the Seahorse
Biosciences XFe24 Flux Analyzer (Agilent Technologies
[Santa Clara, CA]; RRID:SCR_013575) using a procedure
developed in our lab (Sauerbeck et al., 2011; Pandya et
al., 2016; Hubbard et al., 2018). In these experiments,
rotenone, oligomycin, and trifluoromethoxy carbonylcyanide
phenylhydrazone, 2-[2-[4-(trifluoromethoxy)phenyl]
hydrazinylidene]-propanedinitrile (FCCP) were purchased
from Biomol (Plymouth Meeting, PA, USA). All other reagents
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Briefly, 3.5 µg protein equivalent of isolated mitochondria
were suspended in respiration buffer (RB) (125 mM KCl, 2 mM
MgCl2, 0.1% BSA, 20 mM HEPES and 2.5 mM KH2PO4, adjusted
pH 7.2). The combination of substrates/inhibitors/uncoupler
were prepared in RB and 75 µL of each injected as pyruvate
+ malate + adenosine diphosphate (ADP), oligomycin, FCCP,
and rotenone + succinate sequentially through ports A–D at
the final concentrations of 5 mM pyruvate, 2.5 mM malate, 1
mM ADP, 1 µg/mL oligomycin, 4 µM FCCP, 0.1 µM rotenone,
and 10 mM succinate. ADP driven complex I mediated
coupled respiration (State III), ATPase locked leaky respiration
(State IV), complex I driven maximum uncoupled respiration
(State VCI), and complex II-driven maximum respiration (State
VCII) were determined with each subsequent injection. The
results are presented as oxygen consumption rate (OCR) and
expressed as pmol of oxygen consumed per minute.
TaqMan single-tube miRNA RT-qPCR
Isolation of total hippocampal tissue RNA from the cytosolic
and mitochondrial fractions and TaqMan single-tube RT-qPCR
(ThermoFisher) of select miRNA were performed as previously
reported (Wang et al., 2008, 2015). Selected miRNAs for
analysis included miR-146a (Assay ID: 000468), miR-1423p (Assay ID: 000464), miR-142-5p (Assay ID: 002248), miR155 (Assay ID: 002571), miR-150 (Assay ID: 000473), miR-223
(Assay ID: 002295), miR-124a (Assay ID: 001182), and miR19b (Assay ID: 000396). Each miRNA analysis was performed
in technical triplicates of either contralateral or ipsilateral
hippocampi for a total of 6 TBI and 4 sham biological replicates

from each time point (n = 6 TBI, n = 4 sham). The raw cycle
threshold (CT) values were determined using QuantStudioTM
Real-Time PCR Software with automatic baseline and threshold
(ThermoFisher). Overall miRNA levels following TBI or sham
surgery in the cytoplasmic and mitochondrial fractions at each
time point were calculated using formula RQ = 2–(Ct(Ipsi)–Ct(Contra))
(Table 1) comparing the ipsilateral injured side or sham surgery
side relative to the uninjured contralateral side or no surgery
side (RQ: relative quantity). To evaluate the net change of
miRNA enrichment in mitochondria, the following formula was
used: RQ = 2–(Ct(Mito)–Ct(Cyto)) comparing the mitochondria fraction
to cytoplasmic fraction of the same brain side. The calculation
method followed the instructions detailed in the “Guide to
Performing Relative Quantitation of Gene Expression Using
Real-Time Quantitative PCR” (Applied Biosystems).
Gene expression analysis using TaqMan low density array
panel
A customized TaqMan low density array (TLDA) qRT-PCR panel
in an 8 × 48 gene array format (ThermoFisher) was employed
to analyze gene expression in cytosolic fractions from the
injured ipsilateral hippocampi relative to the uninjured
contralateral side. Forty-seven genes including a group of
inflammatory-related marker genes (Gensel et al., 2017)
and an internal control ‘house-keeping’ gene (18S) were
selected for the custom array. The list of genes and their assay
IDs are provided in Additional Table 1. Total cytosolic RNA
(500 ng) was subjected to first-strand cDNA synthesis using
SuperScriptTM III First-Strand Synthesis System (ThermoFisher).
The resulting cDNA from each sample was then combined
with TaqMan Universal PCR Master Mix (No AmpErase UNG,
ThermoFisher) and loaded into each port of the TLDA cards
following manufacturer’s instructions. Quantitative real-time
PCR was performed with a QuantStudioTM 7 Real-Time PCR
System (ThermoFisher) using the manufacturer’s standard
program (hold 2 minutes at 50°C, followed by 10 minutes at
95°C, then 40 cycles of 15 seconds at 95°C and 1 minute at
60°C).
TLDA data processing
Raw qPCR CT (cycle threshold) values from the TLDA card were
first determined using QuantStudioTM Real-Time PCR Software
(ThermoFisher) with automatic baseline and threshold. PCR
data that failed software-defined QC and those CT values equal
to or more than 35 were considered as undetectable and were
given a value of 35. The CT value of 18S ribosomal RNA was
used to obtain ΔCT values of a given sample and the whole
dataset was then further normalized using the Global Mean
Normalization method (Mestdagh et al., 2009) to minimize the
technical variability among array sets. The comparative ∆∆CT
method was used to calculate relative gene expression levels.
Mean ΔΔCT values and standard deviations were calculated
following the “Guide to Performing Relative Quantitation of
Gene Expression Using Real-Time Quantitative PCR” (Applied
Biosystems (2008)). The effect of TBI on each gene in the TLDA
card was expressed as fold change in cytosolic fractions from
the ipsilateral hippocampus relative to uninjured contralateral
side.
Cell permeable peptide-delivery of miRNA mimic in cell
cultures
Cell culture experiments were conducted to document
the ability of a mellitin-derived cell permeable peptide
(p5RHH) to introduce Cy5-labeled miR-146a or scrambled
control (Integrated DNA Technologies, Skokie, IL, USA)
to BV-2 (kind gift from Dr. Linda van Eldik of University of
Kentucky) and SH-SY5H (Cat# CRL-2266, ATCC, Manassas,
VA, USA, RRID:CVCL_0019) cells. The p5RHH peptide
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Table 1 ｜ Changes in miRNA levels in cytoplasmic fractions of hippocampal tissue following TBI and in sham-operated control animals
1d

TBI

Sham

3d

7d

miRNA

Fold (range)

P-value

Fold (range)

P-value

Fold (range)

P-value

miR-124
miR-142-3p
miR-142-5p
miR-146a
miR-150
miR-155
miR-223
miR-19b
miR-124
miR-142-3p
miR-142-5p
miR-146a
miR-150
miR-155
miR-223
miR-19b

0.93 (0.67–1.27)
2.24 (1.61–3.11)
2.62 (2.05–3.35)
1.55 (0.98–2.47)
0.87 (0.59–1.29)
11.54 (6.3–21.3)
15.0 (9.9–22.8)
1.31 (1.06–1.63)
0.90 (0.70–1.17)
0.89 (0.82–1.29)
0.87 (0.70–1.07)
1.05 (0.74–1.48)
0.87 (0.73–1.04)
1.89 (1.27–2.81)
1.67 (1.15–2.43)
1.00 (0.87–1.15)

0.625
0.001
0.0001
0.148
0.541
0.00017
0.000002
0.072
0.711
0.897
0.485
0.865
0.581
0.202
0.095
0.999

0.99 (0.87–1.13)
3.49 (1.97–6.17)
3.41 (2.47–4.70)
1.93 (1.09–3.42)
0.88 (0.66–1.19)
6.18 (3.92–9.72)
3.92 (2.07–7.42)
1.33 (1.04–1.72)
0.86 (0.7–1.05)
1.23 (0.86–1.76)
1.28 (0.68–2.42)
0.96 (0.47–1.98)
0.91 (0.60–1.37)
1.22 (0.44–3.40)
1.61 (0.71–1.82)
0.85 (0.61–1.17)

0.919
0.001
0.0002
0.078
0.678
0.020
0.003
0.028
0.213
0.329
0.520
0.941
0.719
0.735
0.494
0.379

1.03 (0.73–1.45)
0.93 (0.70–1.24)
0.94 (0.72–1.22)
0.93 (0.54–1.58)
0.96 (0.87–1.06)
1.15 (0.73–1.81)
0.66 (0.32–1.35)
0.83 (0.70–0.97)
0.88 (0.27–1.77)
1.50 (0.83–2.71)
1.36 (0.67–2.76)
1.76 (1.25–2.47)
1.07 (0.96–1.19)
3.04 (1.58–5.84)
2.55 (1.82–3.57)
1.39 (1.00–1.94)

0.885
0.886
0.878
0.852
0.548
0.828
0.538
0.318
0.482
0.573
0.701
0.495
0.740
0.355
0.357
0.372

Levels of miRNAs were calculated using the formula: fold change = 2–(Ct(Ipsi)–Ct(Contra)) comparing the ipsilateral injured/sham-operated side of the brain relative
to that of the uninjured/no operated contralateral side of the same animal. Data represent the mean value of the six biological replicates for traumatic brain
injury (TBI) and four biological replicates for sham, and the P-values were generated using two-tailed Student’s t-test (GraphPad 8.0.2). The fold change range
is shown in parentheses. Significantly different expressed miRNAs are highlighted in red (P < 0.05). 1, 3, or 7 days indicates the tissue harvesting time following
controlled cortical impact or sham surgery.

(VLTTGLPALISWIRRRHRRHC) was synthesized by NeoScientific
(Neobiolabs, Cambridge, MA, USA) and a stock of 10 mM
was prepared using protease and nuclease free water,
aliquoted and stored at –80°C. A total of 3 × 105 cells were
seeded into 12-well plates and maintained for 24 hours
in standard cell culture conditions prior to transfection.
Nanoparticle complexes were prepared at a ratio of 200:1
(molar ratio of p5RHH:miR-146a mimic) with 20 nM miR146a using procedures described previously (Hou, 2014).
The p5RHH+miR-146a nanoparticles were then incubated
with BV-2 and SH-SY5Y cells for 24 hours. Additional plated
cells were incubated with Cy5-labeled miR-146a only or
transfected using Lipofectamine RNAiMAX (ThermoFisher) to
assess p5RHH + miR-146a transfection efficiency. Cells were
visualized and photographed using a Nikon C2+ confocal
microscope (Nikon Inc, Melville, NY, USA) and then washed
with PBS and harvested for RNA analysis or Western blot
analysis with either TRAF6 or Actin antibodies.
Peptide-delivery of miRNA mimic to rat brain following CCI
Animals were subjected to a CCI injury and randomly assigned
to receive an intrahippocampal injection of p5RHH + miR146a mimic or scrambled RNA control nanoparticles to test
in vivo effect of the miR-146a mimic on TRAF6 and IRAK1.
Immediately following injury, a Hamilton syringe with a
33-gauge Nanofil (WPI, Sarasota, FL, USA) blunt needle was
slowly lowered in the dorsal hippocampus ipsilateral to the
injury side using stereotaxic coordinates (Paxinos and Watson,
2013) –3.3 mm from bregma, 2.4 mm from midline, and 2.8
mm ventral. The needle was left in place for 1 minute before
injecting a total of 0.5 µL of p5RHH:miR-146a nanoparticles
(ratio of 200:1, 40 nM miR-146a) at a rate of 10 nL/s using
a WPI Ultramicropump III connected to a WPI MICRO2T
SMARTouch controller (WPI, Sarasota, FL, USA). The needle
was left in place for an additional 2 minutes, slowly withdrawn,
and the craniotomy site and overlying skin treated and closed
with sutures. The animals were then euthanatized with CO2 at
48 hours after injection and the hippocampus removed rapidly
and the dorsal hippocampal tissue used to analyze TRAF6 and
IRAK1 gene expression using single-tube TaqMan assays (Wang
et al., 2015) and western blotting for TRAF6.

Protein isolation and western blot analysis
Protein isolation and Western blot analysis were performed
using standard techniques routinely performed in our lab
(Wang et al., 2015). Briefly, RIPA buffer (Cat# R0278; Sigma)
was used to lyse proteins of rat hippocampal tissue, as well as
total cellular protein in transfected cells. Protein concentrations
were determined using BCA protein assay (Cat# 23227, Pierce
Biotechnology, Rockford, IL, USA). For Western blotting, equal
amounts of protein (10–20 µg) were loaded on 4–16% MiniPROTEAN® TGXTM gels (Cat# 456-1106, Bio-Rad, Hercules,
CA, USA) and run at 0.03 A. The gels were then transblotted
onto polyvinylidene fluoride membranes (Cat# 1620177, BioRad) and non-specific binding sites blocked by incubating
the membrane with 5% nonfat milk for 1–2 hours. The blots
were then incubated overnight with primary antibody at 4°C.
Primary antibodies used in this study included anti-TRAF6
(1:1000 dilution; rabbit, Cat# ab33915; Abcam, Cambridge,
MA, USA) and anti-actin (1:2000, rabbit, Cat# A5060; Sigma).
After 3–4 rinses following primary antibody incubation,
blots were incubated with goat anti-rabbit peroxidaseconjugated secondary antibody (Jackson ImmunoResearch
laboratories, Inc. West Grove, Pennsylvania, USA) or IRDye®
800 goat anti-rabbit IgG (1:20,000, Cat# 925-68070, LI-COR,
Lincoln, Nebraska, USA) for 1 hour at room temperature. The
immunoreactive signals were visualized using SuperSignalTM
West Pico PLUS Chemiluminescent Substrate (Pierce
Biotechnology) or using Odyssey CLx (LI-COR, Lincoln).
Statistical analysis
Statistical analysis was carried out using GraphPad Prism
8.0.2 (GraphPad Software Inc., San Diego, CA, USA) Animal
numbers were powered according to published experimental
data and anticipated effect sizes. One-way analysis of variance
and Student’s t-test (two-tailed) were applied to evaluate
mean differences (bioenergetics and miRNA, mRNA singletube assay data) when appropriate. A Student’s t-test was
used to evaluate the difference of the mean fold change
of inflammatory responsive genes between the ipsilateral
and contralateral cytoplasm of qPCR data and western blot
densitometry data. Data are expressed as the mean ± SD
and a P value less than 0.05 was considered as statistically
significant.
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The levels of several non-mitochondria-enriched miRNAs
also exhibited changes over time following TBI with different
trends (Figure 2B). MiR-124a, miR-150, miR19b and a known
TBI-responsive miRNA miR-155 were either increased (such
as miR-124a, miR-155, miR-19b) or not significantly altered
(miR-150) in mitochondria at any time examined following
TBI. One exception was miR-223 (Figure 2B), which is also a
TBI-responsive miRNA that showed significantly decreased
levels in mitochondria at 1 day after TBI (P < 0.01). However,
by 7 days post-injury, the levels of miR-223 were significantly
elevated (P < 0.05) in mitochondria isolated from the
injured hippocampus. No major changes in any of the above
mentioned miRNAs were observed between the ipsilateral
and contralateral hippocampal mitochondria isolated from the
group of sham operated animals (Additional Figure 1).
Interestingly, while levels of the mitochondria-enriched
miRNAs miR-142-3p and miR-142-5p were reduced in
mitochondria at 1 and 3 days following TBI, their levels in
cytoplasmic fractions significantly increased (P < 0.01; Table
1). By 7 days following TBI, the levels of both miR-142-3p
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Figure 1 ｜ Temporal assessment of State III, IV, and VCI and VCII
mitochondrial respiration rates in hippocampal mitochondria after severe
TBI (A) or sham-surgery (B).
Animals (total n = 6 per group for CCI, n = 4 per group for sham surgery) were
euthanatized at 1, 3, or 7 days following injury and the ipsilateral (Ipsi) and
contralateral (Contra) hippocampi were rapidly removed for isolation of the
mitochondria. Mitochondrial bioenergetics was assessed using the Seahorse
Biosciences XFe24 Flux Analyzer. Data are expressed as the mean ± SD. The
difference between the ipsilateral and the contralateral hippocampi was
evaluated using one-way analysis of variance and Student’s t-test. *P < 0.05,
**P < 0.01, ***P < 0.001. OCR: Oxygen consumption rate; TBI: traumatic brain
injury.

B

miR-142-5p
Contra
lpsi

6

*

4

**

2
0

1 day

3 days

7 days

RQ (Mito relative to Cyto)

0.8

Contra
lpsi

0.6
0.4
0.2
0

1 day

miR-155
10
8

3 days

7 days

Contra
lpsi

6
4

**

2
0

1 day

Contra
lpsi

4
2
0

1 day

3 days

7 days

miR-146a

5

3
2
1
0

1 day

Contra
lpsi

3 days

7 days

*

10
5
0

1 day

3 days

miR-19b
Contra
lpsi

4

15

2.5

Contra
lpsi

2.0

7 days

*

*

1.5
1.0
0.5
0

1 day

3 days

7 days

miR-223

3 days

7 days

RQ (Mito relative to Cyto)

**

**

miR-150

miR-124a
1.0

**

6

RQ (Mito relative to Cyto)

8

RQ (Mito relative to Cyto)

RQ (Mito relative to Cyto)

miR-142-3p

RQ (Mito relative to Cyto)

A

RQ (Mito relative to Cyto)

Alteration of the association of mitochondria-enriched
miRNAs following TBI
We reported previously that levels of miR-146a, miR-1423p, and miR-142-5p are highly enriched in the mitochondria
compared to cytosol (Wang et al., 2015). We also found
that the levels of these mitochondria-enriched miRNAs
are decreased in the mitochondrial fraction at early times
following TBI (3 and 12 hours), and that all three miRNAs
increased in cytoplasmic fractions at the same time points
(Wang et al., 2015, 2017). In the present study, we further
investigated levels of these miRNAs at extended times up to
7 days following TBI (Figure 2). When miRNA levels in the
mitochondrial fraction are normalized to that of cytoplasmic
fraction, it provides a relative measure of mitochondrial
enrichment. The enrichment of miR-142-3p and miR-1425p significantly decreased (P = 0.050 and 0.002, respectively)
at 1 day post TBI in mitochondria from the injured ipsilateral
hippocampus compared to the uninjured contralateral
hippocampus (Figure 2A). The mitochondrial enrichment of
these two miRNAs remained significantly lower for up to 3
days (P < 0.01) and returned to near normal levels at 7 days
post-injury. The levels of another mitochondria-enriched
miRNA, miR-146a trended lower at 1 day in the mitochondrial
fraction following TBI with a similar pattern being observed at
3 days. However, by 7 days post-injury, miR-146a levels in the
mitochondrial fraction were found to be significantly elevated
(P = 0.033; Figure 2A).
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1500
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Mitochondria bioenergetics following TBI
The post-injury bioenergetic profile of total mitochondria
isolated from the hippocampus revealed significant changes in
state-dependent oxygen consumption rates (OCR) over time
(Figure 1). The OCR significantly decreased in all four tested
respiration states (P < 0.01, for State III, State VCI, and State
VCII, respectively; P < 0.05 for State IV) in mitochondria isolated
from the ipsilateral hippocampus at 1 day following CCI
relative to intact contralateral side (Figure 1A). At 3 days post
CCI, OCR in mitochondria from the ipsilateral hippocampus
continued to be significantly decreased in State IV and
State VCII (P < 0.05), with near significant decreased levels
in State III (P = 0.058) compared to the contralateral side.
By 1 week post-injury, there were no significant differences
in any respiration state in mitochondria from the injured
hippocampus relative to contralateral side. Sham-surgery did
not result in any significant changes in bioenergetics across all
three time points (Figure 1B).
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Figure 2 ｜ Profile of mitochondria-enrichment of miRNAs following
traumatic brain injury.
Animals (total n = 6 per group) were euthanatized at 1, 3, or 7 days following
injury and the ipsilateral (Ipsi) and contralateral (Contra) hippocampi were
rapidly removed for isolation of the mitochondria (Mito) and cytosolic (Cyto)
fractions. The fractions were then subjected to RNA isolation and miRNA
analysis. The level of mitochondria-enrichment of a miRNA expressed as
relative quantity (RQ) was calculated using the formula RQ = 2–(Ct(Mito)–Ct(Cyto))
where mitochondrial and cytoplasmic fractions were isolated from the same
tissue. (A) Mitochondria-enriched miRNAs. (B) Other miRNAs. Data are
expressed as the mean ± SD. The difference between the ipsilateral and the
contralateral hippocampi was evaluated using one-way analysis of variance
and Student’s t-test. *P < 0.05, **P < 0.01.

and miR-142-5p in the cytoplasmic fraction had returned to
normal. A similar trending pattern was observed for miR-146a.
Finally, levels of two TBI-responsive miRNAs, miRNA miR-155
and miR-223 were significantly elevated in the cytoplasm at 1
and 3 days post-injury and returned to normal levels by 7 days
(see levels and P values in Table 1).
Inflammatory gene expression at different time points
following TBI
A customized TLDA was used to analyze the expression
of selected inflammatory-related genes in hippocampal
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cytoplasm. In general, alterations in gene expression were
found to be most active at 1 day following TBI (Table 2).
By 3 days following TBI, the number and levels of genes
significantly altered were less than that at 1 day, especially
with respect to anti-inflammatory genes (Table 2). Among
the tested genes, there was only one anti-inflammatory gene,
Tgfb1, which remained elevated at 3 days post-injury. Among
the pro-inflammatory genes examined, the chemokine (C-C
motif) ligand 2 (CCL2, also called monocyte chemoattractant
protein 1, MCP1) appeared to have the greatest change
and was significantly elevated in the injured ipsilateral
hippocampus compared to uninjured side by 160- and 15fold respectively at 1 and 3 days post TBI (P < 0.05; Table 2).
By 7 days following TBI, CCL2 levels returned to control values
and we did not observe any significant differences in any of
the other genes in the panel at 7 days between the ipsilateral
injured and contralateral sides.
Effect of miR-146a nanoparticle delivery to BV-2 and
SH-SY5Y cells
MiR-146a targets TRAF6 and IRAK1, two effectors that are
important regulators on the NF-κB pathway (Taganov et al.,
2006). Given our previous observations demonstrating a
differential expression of miR-146a at early hours following
TBI (Wang et al., 2015, 2017), we selected this antiinflammatory miRNA for the peptide-based nanoparticle
delivery studies. We first tested the effects of the peptide/
miR-146a nanoparticle delivery system using the mouse
microglial BV-2 and human neuroblastoma SH-SY5Y cell
line. These two cell lines were incubated with p5RHH + miR146a-Cy5 mimic or scrambled control nanoparticles for 48
hours. Additional cell culture wells were incubated with miR146a-Cy5 mimic (or scrambled control) without any carrier
or in the presence of Lipofectamine RNAiMAX, the latter
of which served as a positive transfection control. Confocal

microscopy demonstrated effective transfection of miR146a-Cy5 in both the BV-2 (Figure 3A) and SH-SY5Y cells
(Additional Figure 2) using p5RHH peptide or Lipofectamine,
while no fluorescent signal was observed in the cells where
transfection carrier agent was not used. These observations
document the necessity of using cell permeable carrier
molecules to ensure cellular delivery of Cy5-labeled miR-146a.
Western blot analysis confirmed the biological activity of miR146a in p5RHH peptide and Lipofectamine transfected cells
as reflected by a significant decrease in TRAF6 protein levels
(P = 0.0005 and 0.013, respectively; Figure 3B and C). These
experiments suggest that the p5RHH + miR-146a nanoparticle
platform effectively delivered miR-146a mimic and downregulated its validated target TRAF6.
Effect of miR-146a delivery to the injured rat hippocampus
The p5RHH peptide was then used to deliver miR-146a
mimic or scrambled control to the rat hippocampus following
severe TBI. The miR-146a mimic-nanoparticle complex
was injected into the dorsal hippocampus immediately
following a severe CCI and animals sacrificed 48 hours later.
Hippocampi were then harvested for analysis of TRAF6
and IRAK1 gene and protein (TRAF6) expression. RT-qPCR
revealed a significant reduction in IRAK1 (P = 0.048) and
TRAF6 (P = 0.036) mRNA levels following miR-146a delivery in
comparison to scrambled control demonstrating the efficacy
of the nanoparticle delivery system (Figure 4A). Importantly,
Western blot analysis demonstrated that TRAF6 protein levels
were also decreased in the hippocampus of animals receiving
p5RHH + miR-146a nanoparticles (Figure 4B).

Discussion
Our previous studies reported that several mitochondriaenriched miRNAs regulating inflammation including miR-142-

Table 2 ｜ Response of inflammatory-related genes in hippocampus following TBI
1d

Anti-inflammatory

Pro-inflammatory

3d

7d

Gene symbol

Fold (range)

P-value

Fold (range)

P-value

Fold (range)

P-value

Arg1
Ccl22
Epas1
Il4
Pparg
Sphk1
Stat6
Tgfb1
Tgm2
Ccr2
Ccl2
Ccr7
Cd86
Il12a
Il12b
Il1b
Il6
Nos2
Stat1
Aif1
Nlrp3
Itgam

0.37 (0.26–0.53)
0.69 (0.3–1.62)
0.61 (0.47–0.78)
0.28 (0.12–0.61)
0.61 (0.44–0.83)
6.10 (3.4–10.9)
0.66 (0.51–0.86)
1.53 (1.2–1.94)
2.40 (1.78–3.24)
10.67 (6.3–18.0)
160 (85.5–299.8)
0.47 (0.3–0.74)
0.87 (0.47–1.59)
0.30 (0.21–0.42)
0.36 (0.24–0.54)
9.46 (6.55–13.7)
0.78 (0.51–1.18)
2.12 (0.47–9.6)
0.89 (0.7–1.14)
1.48 (0.9–1.45)
1.04 (0.77–1.4)
1.56 (1.23–1.98)

0.005
0.550
0.001
0.072
0.032
0.004
0.013
0.006
0.011
0.004
0.002
0.079
0.646
0.001
0.010
0.001
0.392
0.395
0.377
0.510
0.801
0.018

0.54 (0.39–0.75)
0.35 (0.30–0.42)
0.85 (0.63–1.14)
0.57 (0.27–1.23)
0.52 (0.24–1.11)
1.49 (1.03–2.16)
0.92 (0.78–1.09)
2.28 (1.85–2.82)
1.17 (0.99–1.39)
4.93 (3.54–6.88)
15.43 (8.16–29.2)
0.74 (0.45–1.21)
2.51 (1.91–3.31)
0.55 (0.45–0.67)
0.44 (0.30–0.64)
1.58 (1.23–2.04)
0.76 (0.48–1.22)
0.51 (0.43–0.60)
0.98 (0.81–1.18)
3.13 (2.11–4.63)
2.17 (1.82–2.59)
3.07 (2.52–3.74)

0.025
0.151
0.301
0.285
0.178
0.390
0.514
0
0.220
0.007
0.001
0.361
0.007
0
0.057
0.053
0.512
0.098
0.720
0.004
0.001
0.001

1.29 (0.81–2.04)
1.08 (0.64–1.82)
1.21(0.88–1.66)
1.71 (0.73–4.01)
1.01 (0.75–1.37)
0.83 (0.69–1.01)
1.22 (0.95–1.56)
0.60 (0.34–1.07)
1.31 (0.81–2.11)
0.65 (0.21–2.00)
0.47 (0.17–1.27)
1.54 (1.14–2.07)
0.50 (0.28–0.92)
1.26 (0.94–1.67)
0.76 (0.51–1.14)
0.50 (0.27–0.94)
1.13 (0.77–1.68)
0.47 (0.12–1.80)
1.15 (0.87–1.52)
0.54 (0.24–1.19)
0.85 (0.54–1.32)
0.71 (0.41–1.21)

0.340
0.799
0.271
0.351
0.952
0.275
0.155
0.282
0.442
0.505
0.367
0.242
0.290
0.396
0.235
0.458
0.737
0.702
0.314
0.313
0.590
0.419

A TLDA card consisting of selected inflammatory responsive genes was used to assess mRNA expression levels in hippocampal cytoplasm obtained from each
time points following traumatic brain injury (TBI). Gene expression levels were calculated using formula: fold change = 2–(Ct(Ipsi)–Ct(Contra)) comparing the ipsilateral
injured side of the brain relative to the uninjured contralateral side. Data represent the mean value of 4 biological replicates, and the P values were generated
using two-tailed Student’s t-tests. The fold change range is shown in parentheses. Significantly different (P < 0.05) expression genes are highlighted in red for
increased expression and in green for decreased expression. The 1, 3, and 7 days indicate the tissue harvesting time following controlled cortical impact.
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Figure 4 ｜ In vivo delivery of miR-146a mimic using mellitin-derived cell
permeable peptide (p5RHH) effectively reduced levels of TRAF6 and IRAK1
mRNAs and protein levels.
Animals were subjected to controlled cortical impact injury (n = 6) and
randomly assigned to receive an intrahippocampal injection of p5RHH + miR146a mimic (n = 3) or scrambled RNA control (n = 3). The animals were then
euthanatized at 48 hours after injection and the hippocampi removed for
protein and RNA isolation and analysis. (A) TRAF6 and IRAK1 mRNA levels
determined by RT-qPCR following TBI and nanoparticle injections. Data
are expressed as the mean ± SD. The difference between miR-146a and
scramble mimics was evaluated using Student’s t-test. *P < 0.05. (B) Western
blot analysis for TRAF6 using hippocampal tissues that were injected with
either miR-146a or scrambled control mimic. IRAK1: Interleukin-1 receptorassociated kinase 1; TRAF6: TNF receptor-associated factor 6.
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Figure 3 ｜ In vitro delivery of mellitin-derived cell permeable peptide
(p5RHH)-based miR-146a nanoparticles to cultured BV-2 cells.
Confocal microscopy graph of miR-146a and scramble control transfections
(scale bars: 10 µm) (A) and the western blot analysis of TNF receptorassociated factor 6 (TRAF6) in the transfected cells (B). Densitometry
quantification of the western blot analysis from 4 independent transfection
experiments (C, n = 4). Pre-seeded BV-2 cells were incubated either with
miR-146a or scramble mimic/p5RHH-nanoparticle complexes or miR-146a or
scramble mimic/Lipofectamine, or without carrier for 24 hours and the cells
were visualized and photographed using a Nikon C2+ confocal microscope
and then washed with PBS and harvested for RNA analysis or western blot
analysis. The densitometry readout of TRAF6 protein signal was normalized
on that of actin signal in the same protein sample. Data are expressed as
the mean ± SD. The difference between miR-146a and scramble mimics was
evaluated using Student’s t-test. *P < 0.05, ***P < 0.001.

3p, miR-142-5p, and miR-146a are altered in the hippocampus
following a severe traumatic brain injury (Wang et al., 2015,
2017). Specifically, the levels of these miRNAs were reduced
significantly in mitochondria at 3–12 hours following TBI
(Wang et al., 2015, 2017). We now demonstrate that the
levels of these same miRNAs continue to be reduced in
the hippocampal mitochondria for at least 3 days following
TBI, with a concomitant increase in expression levels in the
cytosol. Interestingly, the reduction in mitochondria-enriched
miRNAs coincided with decreased mitochondrial bioenergetics
at the same time points following injury. The results of
these experiments suggest a potential time-dependent
compartmental re-distribution of mitochondria-enriched
miRNAs that is related to TBI-induced loss of mitochondrial
bioenergetics. We further demonstrate the utilization of
a novel cell-penetrating peptide nanoparticle system for
delivery of miR-146a for targeting modulators of NF-κB proinflammatory signaling pathway in vitro and in vivo.
We suggested previously that mitochondria and miRNA
interactions may play a role in miRNA cellular function related
to inflammation in the injured brain (Wang et al., 2015, 2017).
This was based on our observations that levels of miR-146a,
miR-142-3p and miR-142-5p were significantly decreased in
the mitochondrial fraction and increased in the cytoplasmic
fraction at early time points post TBI (Wang et al., 2015). We
hypothesized that this compartmental shift may represent a

translocation of mitochondria-enriched miRNAs in response
to cellular stressors (e.g., TBI) that impact mitochondrial
function. We now show that this compartmental shift is still
evident up to 3 days following TBI for miR-142-3p and miR142-5p in hippocampal tissue, and returns to normal levels by
7 days. Although not statistically significant, alterations in miR146a showed a trend similar to miR-142-3p and miR-142-5p.
It has been well described that TBI elicits a rapid and
significant loss of mitochondrial function in the hippocampus
and is a key factor in determining cell survival and recovery
(Sullivan et al., 1998; Singh et al., 2006). In our current
study, mitochondrial bioenergetics in the hippocampus were
significantly compromised for at least 3 days following TBI and
recovered by 7 days post injury. Interestingly, we observed
that changes in the expression patterns of the mitochondriaenriched, inflammatory miRNAs (miR-142-3p, miR-1425p, and miR-146a) were highly correlated with the loss in
mitochondria bioenergetics. Mitochondria can be considered
as ‘first-responders’ to cellular demands and stressors and can
trigger various signaling pathways involving gene regulation,
in which miRNAs play a critical role. Therefore, we postulate
that mitochondria function may determine the subcellular
localization and function of these mitochondria-enriched
miRNAs. Future studies are needed to understand the
correlation of translocation of these mitochondria-enriched,
inflammatory miRNAs with mitochondrial bioenergetics and
its functional impact on the inflammatory response following
TBI.
Our miRNA and gene expression studies indicate that
alterations of selected inflammatory related miRNAs and
mRNAs peaked at 1 day and their activities remained elevated
at 3 days. The activities were then reduced to control levels
at 1 week following TBI. The inflammatory gene expression
activity observed in this study is consistent with previous
reports (Morganti-Kossmann et al., 2002; Semple et al.,
2010; Ziebell and Morganti-Kossmann, 2010; Morganti et al.,
2016) and may provide the basis for designing miRNA-based
interventional strategies targeting acute times following TBI.
For example, the neuroinflammatory response following TBI
is characterized by a prolonged period of pro-inflammation
persisting for months to years after the injury (Johnson
et al., 2013). However, there also exists a reparative antiinflammatory phase that is only present for acute time points
following TBI (Jin et al., 2012; Hsieh et al., 2013; Kumar et
al., 2016). Therefore, sustaining a balance of inflammatory
responses that maintains expression of the reparative phase
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will be essential to promoting tissue survival and recovery.
We found that miR-146a levels increased in cytoplasm initially,
but then returned to control levels by 7 days post-injury.
These observations are intriguing for at least two reasons.
First, miR-146a plays a significant role in regulating the
production of certain pro-inflammatory cytokines by targeting
two adaptor proteins TRAF6 and IRAK1 that function upstream
of the NF-κB signaling pathway (Liu et al., 2017). Second,
miR-146a expression is actually regulated by activation
of the NF-κB pathway (Taganov 2006). Thus, miR-146a is
activated by and also acts as a negative feedback regulator
of NF-κB signaling (Figure 5), which may enable a fine-tune
control of the inflammatory response. Taken together, it is
postulated that the transient expression of anti-inflammatory
reparative signaling may be related to the downregulation
of miR-146a through NF-κB. While the mechanisms by
which miR-146a modulates inflammatory signaling in the
injured brain are currently not known, these observations
prompted us to test whether nanoparticle delivery of miR146a can serve as a therapeutic strategy for modulating the
neuroinflammatory response following TBI. Specifically, we
employed a cell-permeable peptide p5RHH to deliver miR146a mimic to cultured cell lines and also following TBI. The
p5RHH cell-permeable peptide forms a non-immunogenic
nanoparticle complex with small inhibitory RNA molecules
and has been shown to be an effective delivery platform (Hou
et al., 2013a; Hou et al., 2013b). Our data demonstrated that
p5RHH effectively delivered miR-146a mimic and reduced
the expression levels of TRAF6 and IRAK1 in vitro and in vivo.
The results of these studies are encouraging as they establish

a proof of principle that this novel nanoparticle delivery
approach has therapeutic potential for modulating proinflammatory effectors in the injured brain.
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